The APAC amniotic products market is expected to grow from US$ 251.74 million in 2022 to US$ 582.01 million by 2028; it is estimated to grow at a CAGR of 8.8% from 2022 to 2028.
Regenerative medicine is concerned with the functional regeneration of tissues and organs in patients suffering from catastrophic injuries and chronic diseases. The phenomenal breakthrough in stem cell research has provided the groundwork for cell-based therapeutics for resistant diseases to traditional treatments. Stem cells are the boundaries of regenerative medicine because of their unlimited self-renewal and ability to differentiate into numerous types of cells. Ex vivo remodeling of stem cells grown into 3D organoids and tissue architectures for tailored applications has been endorsed by advances in gene editing and tissue engineering technology. In recent years, stem cell therapy has become a promising and advanced scientific study area. Due to its excellent trapping capabilities, it can also be used as a nano-reservoir for drug administration. In the clinic, the Amnio-M has evolved from a simple sheet for topical applications for skin and corneal repair to more advanced forms, such as micronized dehydrated membrane, amniotic cytokine extract, and solubilized powder injections to regenerate muscles, cartilage, and tendons, over the last century. Thus, the increasing demand for amniotic membranes in stem cell research and regenerative medicine is anticipated to boost the demand for amniotic products, resulting in market growth during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC amniotic products market . The APAC amniotic products market is expected to grow at a good CAGR during the forecast period.
Regenerative medicine is concerned with the functional regeneration of tissues and organs in patients suffering from catastrophic injuries and chronic diseases. The phenomenal breakthrough in stem cell research has provided the groundwork for cell-based therapeutics for resistant diseases to traditional treatments. Stem cells are the boundaries of regenerative medicine because of their unlimited self-renewal and ability to differentiate into numerous types of cells. Ex vivo remodeling of stem cells grown into 3D organoids and tissue architectures for tailored applications has been endorsed by advances in gene editing and tissue engineering technology. In recent years, stem cell therapy has become a promising and advanced scientific study area. Due to its excellent trapping capabilities, it can also be used as a nano-reservoir for drug administration. In the clinic, the Amnio-M has evolved from a simple sheet for topical applications for skin and corneal repair to more advanced forms, such as micronized dehydrated membrane, amniotic cytokine extract, and solubilized powder injections to regenerate muscles, cartilage, and tendons, over the last century. Thus, the increasing demand for amniotic membranes in stem cell research and regenerative medicine is anticipated to boost the demand for amniotic products, resulting in market growth during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC amniotic products market . The APAC amniotic products market is expected to grow at a good CAGR during the forecast period.
APAC Amniotic Products Market Segmentation
The APAC amniotic products market is bifurcated based on type, application, end user and country.- Based on type, the market is segmented into amniotic membranes, and amniotic suspensions. The amniotic membranes segment dominated the market in 2022 and is expected to be fastest growing during forecast period.
- Based on application, the market is segmented into wound care, orthopedics, ophthalmology, and other applications. The wound care segment dominated the market in 2022 and orthopedics segment is expected to be fastest growing during forecast period.
- Based on end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market in 2022 and ambulatory surgical centers segment is expected to be fastest growing during forecast period.
- Based on country, the APAC amniotic products market is segmented into China, Japan, India, Australia, South Korea, and Rest of APAC.
Table of Contents
1. Introduction
3. Research Methodology
4. APAC Amniotic Products Market - Market Landscape
5. APAC Amniotic Products Market- Key Market Dynamics
6. Amniotic Products Market- APAC Analysis
7. APAC Amniotic Products Market Revenue and Forecast to 2028 - by Type
8. APAC Amniotic Products Market Revenue and Forecast to 2028 - by Application
9. APAC Amniotic Products Market Revenue and Forecast to 2028 - by End User
10. APAC Amniotic Products Market Revenue and Forecast to 2028 - by Country
11. APAC Amniotic Products Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Integra LifeSciences
- Katena Products. Inc.
- MiMedx
- NuVision Biotherapies Ltd
- Organogenesis, Inc.
- Sanuwave and Sanuwave Health, Inc.
- Smith & Nephew
- Stryker
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 133 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 251740 Million |
| Forecasted Market Value ( USD | $ 582010 Million |
| Compound Annual Growth Rate | 15.0% |
| Regions Covered | Asia Pacific |
